Overview

• Jubilant Pharmova’s net profit for Q1FY26 fell 78.65% year-on-year to ₹102.90 crore from ₹482.10 crore.
• Revenue from operations rose 9.2% to ₹1,878.9 crore in the June quarter.
• CFO Arvind Chokhany resigned following the earnings release, triggering a 4.2% decline in the share price on the BSE.
• The company plans to launch six to eight products annually in US and non-US markets and ramp up exports.
• Global clinical trials for JBI-802 and JBI-778 are actively enrolling patients, reflecting ongoing R&D progress.